特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

臨床試験の世界市場 (2020-2027年):フェーズI・フェーズII・フェーズIII・フェーズIV

Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, And Segment Forecasts, 2020 - 2027

発行 Grand View Research, Inc. 商品コード 940769
出版日 ページ情報 英文 120 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
臨床試験の世界市場 (2020-2027年):フェーズI・フェーズII・フェーズIII・フェーズIV Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, And Segment Forecasts, 2020 - 2027
出版日: 2020年05月20日 ページ情報: 英文 120 Pages
概要

世界の臨床試験の市場は予測期間中5.1%のCAGRで推移し、2027年には699億米ドルの規模に成長すると予測されています。医薬品業界では、癌、呼吸器疾患、糖尿病、心血管疾患などの慢性疾患に対する新薬開発のニーズに迫られています。また、新型コロナウイルス感染症 (COVID-19) の治療薬開発への需要の市場の成長を牽引しています。現在、288の治療薬と106のワクチンが開発中とされており、このうちの約7.0%がフェーズIV、21.0%がフェーズIII、43.0%がフェーズII、13.0%がフェーズIの段階にあります。

当レポートでは、世界の臨床試験の市場を調査し、市場および製品の概要、市場成長への各種影響因子の分析、市場規模・市場シェアの予測、フェーズ・設計・適応症・地域/主要国など各種区分別の内訳、主要企業プロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 臨床試験市場の可変因子・動向・展望

  • 市場の展望
  • 普及率・成長率の見通し
  • 製品パイプライン分析:ステージ別
  • 臨床試験の迅速な追跡
  • 連帯臨床試験
  • 仮想臨床試験
  • COVID-19の影響
  • 市場力学
  • 臨床試験:市場分析ツール

第4章 市場分析・予測:フェーズ別

  • 定義・範囲
  • 市場シェア分析実績・予測
  • 概要
  • 市場規模の推移・予測
  • 動向分析

第5章 市場分析・予測:研究設計別

  • 定義・範囲
  • 市場シェア分析実績・予測
  • 概要
  • 市場規模の推移・予測
  • 動向分析

第6章 市場分析・予測:適応症別

  • 定義・範囲
  • 市場シェア分析実績・予測
  • 概要
  • 市場規模の推移・予測
  • 動向分析

第7章 市場分析・予測:地域別

  • 定義・範囲
  • 市場シェア分析実績・予測
  • 概要
  • 市場シェア実績
  • 市場規模の推移・予測
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合分析

  • 主要企業のプロファイル
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Clinical Trials Market, By Region 2016 - 2027 (USD Million)
  • Table 4 Global Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 5 Global Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 7 Global Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 8 North America Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
  • Table 9 North America Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 10 North America Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 12 North America Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 13 U.S. Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 14 U.S. Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 16 U.S. Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 17 Canada Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 18 Canada Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 20 Canada Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 21 Europe Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
  • Table 22 Europe Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 23 Europe Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 25 Europe Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 26 UK Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 27 UK Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 29 UK Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 30 Germany Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 31 Germany Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 33 Germany Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 34 France Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 35 France Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 37 France Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 38 Italy Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 39 Italy Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 41 Italy Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 42 Spain Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 43 Spain Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 45 Spain Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 46 Asia Pacific Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
  • Table 47 Asia Pacific Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 48 Asia Pacific Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 50 Asia Pacific Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 51 India Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 52 India Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 54 India Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 55 Japan Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 56 Japan Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 58 Japan Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 59 China Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 60 China Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 62 China Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 63 Australia Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 64 Australia Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 66 Australia Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 67 South Korea Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 68 South Korea Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 70 South Korea Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 71 Latin America Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
  • Table 72 Latin America Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 73 Latin America Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 75 Latin America Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 76 Brazil Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 77 Brazil Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 79 Brazil Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 80 Mexico Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 81 Mexico Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 83 Mexico Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 84 Argentina Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 85 Argentina Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 87 Argentina Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 88 Colombia Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 89 Colombia Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 91 Colombia Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 92 MEA Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
  • Table 93 MEA Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 94 MEA Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 96 MEA Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 97 South Africa Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 98 South Africa Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 100 South Africa Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 101 Saudi Arabia Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 102 Saudi Arabia Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 104 Saudi Arabia Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 105 UAE Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 106 UAE Clinical Trials Market, By Study Design, 2016 - 2027 (USD Million)
  • Table 108 UAE Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value - chain - based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Clinical Trials Market:Market snapshot
  • Fig. 9 Clinical Trials Market:Market segmentation
  • Fig. 10 Clinical Trials Market Strategy framework
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Clinical Trials Market driver impact
  • Fig. 14 Clinical Trials Market restraint impact
  • Fig. 15 Clinical Trials Market porter's five forces analysis
  • Fig. 16 Clinical Trials Market PESTEL analysis
  • Fig. 17 Clinical Trials Market segment dashboard
  • Fig. 18 Clinical Trials Market: Phase movement Analysis
  • Fig. 19 Phase I estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 20 Phase II estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 21 Phase III estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 22 Phase IV estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 23 Clinical Trials Market segment dashboard
  • Fig. 24 Clinical Trials Market: Study Design Movement Analysis
  • Fig. 25 Interventional market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 26 Observational market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 27 Expanded Access market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 28 Clinical Trials Market: Segment dashboard
  • Fig. 29 Clinical Trials Market: Indication movement analysis
  • Fig. 30 Autoimmune/inflammation market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 31 Pain management market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 32 Oncology market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 33 CNS condition market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 34 Diabetes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 35 Obesity market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 36 Cardiovascular market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 37 Others market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 38 Global Clinical Trials Market: Regional movement analysis
  • Fig. 39 Global Clinical Trials Market: Regional outlook and key takeaways
  • Fig. 40 Global market share, by region
  • Fig. 41 North America market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 42 U.S. market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 43 Canada market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 44 Europe market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 45 UK market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 46 Germany market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 47 France market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 48 Italy market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 49 Spain market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 50 Asia Pacific market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 51 China market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 52 Japan market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 53 India market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 54 Australia market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 55 South Korea market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 56 Latin America market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 57 Brazil market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 58 Mexico market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 59 Argentina market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 60 Colombia market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 61 Middle East and Africa. market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 62 South Africa market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 63 Saudi Arabia market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 64 UAE market estimates and forecast, 2016 - 2027 (USD Million)
目次
Product Code: GVR-1-68038-975-3

Clinical Trials Market Growth & Trends

The global clinical trials market size is expected to reach USD 69.9 billion by 2027, according to a new report by Grand View Research, Inc. It is projected to exhibit a CAGR of 5.1% during the forecast period. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and other products. Also, clinical trials have become increasingly costly ventures, adding to the overall cost of developing a drug. Hence, big pharmaceuticals as well as small biotechnology firms are looking for innovative ways to improve trial outcomes and decrease trial costs.

The increasing need to develop new therapeutics for chronic diseases such as cancer, respiratory disorder, diabetes, cardiovascular disease, and others is creating immense pressure on healthcare. The global pandemic caused due to COVID-19 (coronavirus) and the increasing demand for developing a suitable treatment for the same is driving the market growth. The number of people affected by the coronavirus has reached one million, which further depicts an increasing need for therapeutics and vaccines. Currently, there are 288 therapeutics and 106 vaccines in development. Out of this, nearly 7.0% therapeutics are in Phase IV, 21.0% in Phase III, 43.0% & 13.0% in Phase II & Phase I respectively.

The pandemic has also resulted in global disruption of traditional onsite clinical trials. Hence, the regulatory bodies all over the world have launched various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the World Health Organization (WHO) to find effective treatment against COVID-19.

Though COVID-19 is forcing many medical device & drug developers to revise the approach they prepare for these types of crises, integrating best practices within clinical trial procedures and adapting to virtual trials can support continuous development of therapeutics even in the presence of this pandemic.

Clinical Trials Market Report Highlights

Phase III clinical trials dominated the market with a revenue share of 53.0% in 2019. This is attributed to the complexity level associated with this phase

Interventional design segment accounted for the largest market share of 45.6% in 2019 in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers

North America held 51.2% of market share in 2019. Favorable government initiatives and presence of large numbers of players in U.S. offerings advanced services are responsible for the growth

Asia Pacific is expected to expand at the fastest CAGR of 6.1% over the forecast period owing to the increasing patient pool and cost efficient services

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Phase
    • 1.1.2. Study Design
    • 1.1.3. Indication
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1: Understanding the market dynamics
    • 1.9.2. Objective 2: Understanding the market estimates and forecasts
    • 1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
    • 1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Product Pipeline Analysis, by Stage
    • 3.3.1. Therapeutics in development
    • 3.3.2. Vaccines in development
  • 3.4. Fast track of clinical trials
    • 3.4.1. FDA initiative -CTPA
    • 3.4.2. UK initiative -ACCORD
    • 3.4.3. ASIA Pacific initiative - DCGI
    • 3.4.4. University of Pittsburgh School of Medicine-UPMC
  • 3.5. Solidarity clinical trials
    • 3.5.1. Participation in solidarity trials
    • 3.5.2. Solidarity clinical trial for vaccines
  • 3.6. Virtual clinical trials
    • 3.6.1. In-home clinical services
  • 3.7. COVID-19 impact on clinical trials
    • 3.7.1. Companies with phase 1 trial disruption
    • 3.7.2. Companies with phase 2 trial disruption
    • 3.7.3. Companies with phase 3 trial disruption
  • 3.8. Market Dynamics
    • 3.8.1. Market Driver Analysis
      • 3.8.1.1. Increasing research and development promoting outsourcing
      • 3.8.1.2. Adoption of new technology in clinical research
      • 3.8.1.3. Increasing prevalence of chronic disease
      • 3.8.1.4. Globalization of clinical trials
    • 3.8.2. Market Restraint Analysis
      • 3.8.2.1. Stringent regulatory policies for patient enrollment
      • 3.8.2.2. Lack of skilled workforce in clinical research
    • 3.8.3. Industry Challenges
      • 3.8.3.1. Rising cost of clinical trial
  • 3.9. Clinical Trials: Market Analysis Tools
    • 3.9.1. Industry Analysis - Porter's
      • 3.9.1.1. Supplier Power
      • 3.9.1.2. Buyer Power
      • 3.9.1.3. Substitution Threat
      • 3.9.1.4. Threat from new entrant
      • 3.9.1.5. Competitive rivalry
    • 3.9.2. PESTEL Analysis
      • 3.9.2.1. Political Landscape
      • 3.9.2.2. Environmental Landscape
      • 3.9.2.3. Social Landscape
      • 3.9.2.4. Technology Landscape
      • 3.9.2.5. Legal Landscape
    • 3.9.3. Major Deals & Strategic Alliances Analysis

Chapter 4. Clinical Trials Market: Segment Analysis, by Phase, 2016 - 2027 (USD Million)

  • 4.1. Definitions & Scope
  • 4.2. Phase market share analysis, 2019 & 2027
  • 4.3. Segment Dashboard
  • 4.4. Global Clinical Trials Market, by Phase, 2016 to 2027
  • 4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027for the following
    • 4.5.1. Phase I
    • 4.5.2. Phase II
    • 4.5.3. Phase III
    • 4.5.4. Phase IV

Chapter 5. Clinical Trials Market: Segment Analysis, By Study Design, 2016 - 2027 (USD Million)

  • 5.1. Definitions & Scope
  • 5.2. Study Design market share analysis, 2019 & 2027
  • 5.3. Segment Dashboard
  • 5.4. Global Clinical Trials Market, By Study Design, 2016 to 2027
  • 5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 5.5.1. Interventional
    • 5.5.2. Observational
    • 5.5.3. Expanded Access

Chapter 6. Clinical Trials Market: Segment Analysis, By Indication, 2016 - 2027 (USD Million)

  • 6.1. Definitions & Scope
  • 6.2. Indication market share analysis, 2019 & 2027
  • 6.3. Segment Dashboard
  • 6.4. Global Clinical Trials Market, By Indication, 2016 to 2027
  • 6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 6.5.1. Autoimmune/inflammation
    • 6.5.2. Pain management
    • 6.5.3. Oncology
    • 6.5.4. CNS condition
    • 6.5.5. Diabetes
    • 6.5.6. Obesity
    • 6.5.7. Cardiovascular
    • 6.5.8. Others

Chapter 7. Clinical Trials Market: Regional Market Analysis, by Phase, 2016 - 2027 (USD Million)

  • 7.1. Definitions & Scope
  • 7.2. Regional Market Share Analysis, 2019 & 2027
  • 7.3. Regional Market Dashboard
  • 7.4. Regional Market Snapshot
  • 7.5. Regional Market Share, 2019
  • 7.6. Market Size, & Forecasts, and Trend Analysis, 2016 to 2027:
  • 7.7. North America
    • 7.7.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.7.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
    • 7.7.3. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
    • 7.7.4. Market estimates and forecast, By Indication, 2016 - 2027 (USD Million)
    • 7.7.5. U.S.
      • 7.7.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.7.5.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.7.5.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.7.6. Canada
      • 7.7.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.7.6.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.7.6.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
  • 7.8. Europe
    • 7.8.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.8.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
    • 7.8.3. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
    • 7.8.4. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.8.5. Germany
      • 7.8.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.8.5.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.8.5.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.8.6. UK
      • 7.8.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.8.6.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.8.6.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.8.7. France
      • 7.8.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.8.7.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.8.7.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.8.8. Italy
      • 7.8.8.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.8.8.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.8.8.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.8.9. Spain
      • 7.8.9.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.8.9.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.8.9.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
  • 7.9. Asia Pacific
    • 7.9.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.9.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
    • 7.9.3. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
    • 7.9.4. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.9.5. China
      • 7.9.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.9.5.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.9.5.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.9.6. Japan
      • 7.9.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.9.6.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.9.6.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.9.7. India
      • 7.9.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.9.7.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.9.7.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.9.8. Australia
      • 7.9.8.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.9.8.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.9.8.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.9.9. South Korea
      • 7.9.9.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.9.9.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.9.9.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
  • 7.10. Latin America
    • 7.10.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.10.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
    • 7.10.3. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
    • 7.10.4. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.10.5. Brazil
      • 7.10.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.10.5.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.10.5.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.10.6. Mexico
      • 7.10.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.10.6.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.10.6.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.10.7. Argentina
      • 7.10.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.10.7.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.10.7.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.10.8. Colombia
      • 7.10.8.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.10.8.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.10.8.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
  • 7.11. Middle East and Africa
    • 7.11.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.11.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
    • 7.11.3. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
    • 7.11.4. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.11.5. South Africa
      • 7.11.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.11.5.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.11.5.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.11.6. Saudi Arabia
      • 7.11.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.11.6.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.11.6.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
    • 7.11.7. UAE
      • 7.11.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 7.11.7.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
      • 7.11.7.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

Chapter 8. Clinical Trials Market- Competitive Analysis

  • 8.1. Key companies profiled
    • 8.1.1. IQVIA
      • 8.1.1.1. Company Overview
      • 8.1.1.2. Financial Performance
      • 8.1.1.3. Product Benchmarking
      • 8.1.1.4. Strategic Initiatives
    • 8.1.2. PAREXEL International Corporation
      • 8.1.2.1. Company Overview
      • 8.1.2.2. Financial Performance
      • 8.1.2.3. Product Benchmarking
      • 8.1.2.4. Strategic Initiatives
    • 8.1.3. Pharmaceutical Product Development, LLC
      • 8.1.3.1. Company Overview
      • 8.1.3.2. Financial Performance
      • 8.1.3.3. Product Benchmarking
      • 8.1.3.4. Strategic Initiatives
    • 8.1.4. Charles River Laboratory
      • 8.1.4.1. Company Overview
      • 8.1.4.2. Financial Performance
      • 8.1.4.3. Product Benchmarking
      • 8.1.4.4. Strategic Initiatives
    • 8.1.5. ICON Plc
      • 8.1.5.1. Company Overview
      • 8.1.5.2. Financial Performance
      • 8.1.5.3. Product Benchmarking
      • 8.1.5.4. Strategic Initiatives
    • 8.1.6. Wuxi AppTec Inc
      • 8.1.6.1. Company Overview
      • 8.1.6.2. Financial Performance
      • 8.1.6.3. Product Benchmarking
      • 8.1.6.4. Strategic Initiatives
    • 8.1.7. PRA Health Sciences
      • 8.1.7.1. Company Overview
      • 8.1.7.2. Financial Performance
      • 8.1.7.3. Product Benchmarking
      • 8.1.7.4. Strategic Initiatives
    • 8.1.8. SGS SA
      • 8.1.8.1. Company Overview
      • 8.1.8.2. Financial Performance
      • 8.1.8.3. Product Benchmarking
      • 8.1.8.4. Strategic Initiatives
    • 8.1.9. Syneos Health
      • 8.1.9.1. Company Overview
      • 8.1.9.2. Financial Performance
      • 8.1.9.3. Product Benchmarking
      • 8.1.9.4. Strategic Initiatives
    • 8.1.10. Chiltern International Ltd
      • 8.1.10.1. Company Overview
      • 8.1.10.2. Financial Performance
      • 8.1.10.3. Product Benchmarking
      • 8.1.10.4. Strategic Initiatives
    • 8.1.11. Eli Lilly and Company
      • 8.1.11.1. Company Overview
      • 8.1.11.2. Financial Performance
      • 8.1.11.3. Product Benchmarking
      • 8.1.11.4. Strategic Initiatives
    • 8.1.12. Novo Nordisk A/S
      • 8.1.12.1. Company Overview
      • 8.1.12.2. Financial Performance
      • 8.1.12.3. Product Benchmarking
      • 8.1.12.4. Strategic Initiatives
    • 8.1.13. Pfizer
      • 8.1.13.1. Company Overview
      • 8.1.13.2. Financial Performance
      • 8.1.13.3. Product Benchmarking
      • 8.1.13.4. Strategic Initiatives
    • 8.1.14. Clinipace
      • 8.1.14.1. Company Overview
      • 8.1.14.2. Financial Performance
      • 8.1.14.3. Product Benchmarking
      • 8.1.14.4. Strategic Initiatives